Skip to main content
All lobbying filings

NOVOCURE INC.

Lobbying for NOVOCURE INC.

 Filing 4th Quarter - Report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 17, 2026
Expenses
$110,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Pennsylvania

Official filing document

 Lobbyists on this filing 2
  • KATHERINE MEYER
    Previously held: Senior Policy Advisor, Office of House Republican Leader Kevin McCarthy; Deputy Health Policy Director, Senate Finance Committee; Health Policy Advisor, Senator Orrin Hatch; Sr. LA, Congressman Erik Paulsen; LA, Congressman Jeff Fortenberry
  • ELLE WHITSON
    Previously held: Covered Official Positions Continued: Health Policy Advisor, Congresswoman Cathy McMorris Rogers; Staff Assistant / Legislative Correspondent / Legislative Assistant, Congressman Ryan Costello

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 3
  • Health & Human Services, Dept of (HHS)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 2
  • HR 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Lobbying activity 2
Medicare/Medicaid

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Tariff (miscellaneous tariff bills)

Tariff issues, specifically related to medical device 232.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem